secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001437749-25-016867
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic Q1 2025 revenue $394K, net loss $2.028M; cash $7.3M; progress on C1 platform grants
--------------------------------------------------------------------------------

- Revenue $394K, up from $335K YoY, driven by $210K in Gates Foundation and CEPI grant revenue.
- Net loss $2.028M vs $2.01M YoY; operating loss improved to $2.002M from $2.126M.
- Cash, cash equivalents and securities $7.3M at March 31, 2025, down from $9.3M at Dec 31, 2024.
- Up to $4.5M CEPI grant and $3M Gates Foundation grant advancing C1 platform for vaccines and antibodies.
- Commercial launch of recombinant Human Serum Albumin expected Q3 2025; dairy enzyme launch late 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774925016867/0001437749-25-016867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774925016867/dyai20250107_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer